Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Restructuring Costs (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of Restructuring Costs data on record, last reported at $8.6 million in Q3 2025.

  • For Q3 2025, Restructuring Costs rose 15.02% year-over-year to $8.6 million; the TTM value through Sep 2025 reached $32.4 million, changed N/A, while the annual FY2024 figure was $29.6 million, 8.55% up from the prior year.
  • Restructuring Costs reached $8.6 million in Q3 2025 per GLUE's latest filing, up from $7.8 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $8.6 million in Q3 2025 and bottomed at $6.8 million in Q1 2024.